---
title: Benidipine + Chlorthalidone + Telmisartan
description: >-
  - This combination drug is primarily prescribed for the management of
  **hypertension (high blood pressure)**. It is used in adults when blood
  pressure is not adequately controlled by individual components or two-drug
  combinations.  It may also reduce the risk of cardiovascular events like heart
  a...
is_banned: false
lastModified: '2025-09-22T17:22:08.149Z'
faqs:
  - q: >-
      What is the recommended dosage for Benidipine + Chlorthalidone +
      Telmisartan?**


      **A:** The standard adult dose is Benidipine 4mg + Chlorthalidone 12.5mg +
      Telmisartan 40mg once daily, but this might change depending on the
      patient's specific situation. This combination is generally not
      recommended for children.
    a: >-
      A:** The standard adult dose is Benidipine 4mg + Chlorthalidone 12.5mg +
      Telmisartan 40mg once daily, but this might change depending on the
      patient's specific situation. This combination is generally not
      recommended for children.
  - q: >-
      What are the main side effects?**


      **A:** Common side effects include dizziness, headache, fatigue, nausea,
      and low blood pressure.
    a: >-
      A:** Common side effects include dizziness, headache, fatigue, nausea, and
      low blood pressure.
  - q: >-
      Can this combination be used during pregnancy or breastfeeding?**


      **A:** No, it is contraindicated in both pregnancy and breastfeeding due
      to potential harm to the fetus or neonate.
    a: >-
      A:** No, it is contraindicated in both pregnancy and breastfeeding due to
      potential harm to the fetus or neonate.
  - q: >-
      What are the major drug interactions to be aware of?**


      **A:** Significant interactions can occur with diuretics, potassium
      supplements, lithium, NSAIDs, and CYP3A4 inhibitors.
    a: >-
      A:** Significant interactions can occur with diuretics, potassium
      supplements, lithium, NSAIDs, and CYP3A4 inhibitors.
  - q: >-
      What should be monitored in patients taking this combination?**


      **A:** Blood pressure, renal function, electrolytes, and liver function
      tests should be regularly monitored.
    a: >-
      A:** Blood pressure, renal function, electrolytes, and liver function
      tests should be regularly monitored.
  - q: >-
      What conditions does this combination treat?**


      **A:** Primarily, it is indicated for the treatment of hypertension (high
      blood pressure).
    a: >-
      A:** Primarily, it is indicated for the treatment of hypertension (high
      blood pressure).
  - q: >-
      Are there any dietary restrictions while on this medication?**


      **A:** Patients should limit their intake of potassium-rich foods and
      avoid alcohol.
    a: >-
      A:** Patients should limit their intake of potassium-rich foods and avoid
      alcohol.
  - q: >-
      What should a patient do if they miss a dose?**


      **A:** If a dose is missed, take it as soon as remembered unless it is
      close to the next scheduled dose. Do not double the dose.
    a: >-
      A:** If a dose is missed, take it as soon as remembered unless it is close
      to the next scheduled dose. Do not double the dose.
  - q: >-
      Is this combination safe for patients with kidney or liver problems?**


      **A:** Caution is advised in patients with kidney or liver problems. Dose
      adjustment may be necessary depending on the severity of impairment.
    a: >-
      A:** Caution is advised in patients with kidney or liver problems. Dose
      adjustment may be necessary depending on the severity of impairment.
  - q: >-
      What is the mechanism of action of this triple-drug therapy?**


      **A:** It combines the actions of a calcium channel blocker (Benidipine),
      a diuretic (Chlorthalidone), and an angiotensin II receptor blocker
      (Telmisartan) to lower blood pressure through various mechanisms.
    a: >-
      A:** It combines the actions of a calcium channel blocker (Benidipine), a
      diuretic (Chlorthalidone), and an angiotensin II receptor blocker
      (Telmisartan) to lower blood pressure through various mechanisms.
---
## **Usage**

- This combination drug is primarily prescribed for the management of **hypertension (high blood pressure)**. It is used in adults when blood pressure is not adequately controlled by individual components or two-drug combinations.  It may also reduce the risk of cardiovascular events like heart attack and stroke.
- **Pharmacological Classification:** Antihypertensive (This classification encompasses the three drug classes present: calcium channel blocker, thiazide-like diuretic, and angiotensin II receptor blocker).
- **Mechanism of Action:** This triple-combination therapy targets multiple pathways involved in blood pressure regulation. Benidipine, a dihydropyridine calcium channel blocker, relaxes and widens blood vessels by blocking calcium influx into vascular smooth muscle. Chlorthalidone, a thiazide-like diuretic, increases the excretion of sodium and water, reducing blood volume. Telmisartan, an angiotensin II receptor blocker (ARB), prevents angiotensin II from constricting blood vessels.  The combined effect leads to a significant reduction in blood pressure.

## **Alternate Names**

- No widely recognized alternate generic names exist internationally. Regional variations might be present.
- **Brand Names:** Benitowa Trio, Benidin Trio, and others. (Note: Brand names may vary by region.)

## **How It Works**

- **Pharmacodynamics:** This combination exerts its antihypertensive effect by reducing peripheral vascular resistance and lowering blood volume. Benidipine relaxes vascular smooth muscle, Chlorthalidone reduces blood volume through diuresis, and Telmisartan blocks the vasoconstricting effects of angiotensin II.
- **Pharmacokinetics:**  Absorption, distribution, metabolism, and elimination specifics for this exact combination may not be readily available. However, Benidipine is well-absorbed orally, and telmisartan is metabolized hepatically. Chlorthalidone has a long half-life. Renal impairment would affect chlorthalidone and telmisartan excretion. The elimination pathways mainly include renal and hepatic excretion, metabolism by CYP enzymes (especially for Benidipine and Telmisartan).
- **Mode of Action:**  Benidipine blocks L-type calcium channels in vascular smooth muscle. Chlorthalidone inhibits sodium reabsorption in the distal convoluted tubule of the nephron. Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor.
- **Receptor Binding, Enzyme Inhibition, or Neurotransmitter Modulation:** Telmisartan exhibits AT1 receptor antagonism. Benidipine acts on L-type calcium channels. Chlorthalidone does not directly bind to receptors, inhibit enzymes, or modulate neurotransmitters in its principal antihypertensive actions.

## **Dosage**

The dosage information provided below is for informational purposes only and should not be interpreted as medical advice.  Always consult with a qualified healthcare professional for personalized dosing recommendations.

### **Standard Dosage**

#### **Adults:**  A typical starting dose may involve a combination tablet containing Benidipine 4 mg, Chlorthalidone 12.5 mg, and Telmisartan 40 mg once daily.  Dose adjustment may be necessary based on individual patient response.


#### **Children:** This combination is generally not recommended for children under 18 years of age due to limited safety and efficacy data.

#### **Special Cases:**

- **Elderly Patients:** Initiate therapy with caution and at the lowest effective dose. Close monitoring is essential.
- **Patients with Renal Impairment:** Dose adjustment might be needed depending on the degree of impairment. Closely monitor renal function.
- **Patients with Hepatic Dysfunction:** Initiate therapy with caution and at the lowest effective dose. Monitor liver function.
- **Patients with Comorbid Conditions:** Careful evaluation and individual dose adjustments are essential, especially in patients with diabetes, cardiovascular diseases, or electrolyte imbalances.

### **Clinical Use Cases**

Dosage recommendations for intubation, surgical procedures, mechanical ventilation, ICU use, and emergency situations are not specifically established for this combination. In such cases, the individual components may be administered separately under strict medical supervision.

### **Dosage Adjustments**

Dose adjustments might be required based on renal or hepatic dysfunction, metabolic disorders, or genetic polymorphisms affecting drug metabolism.


## **Side Effects**

### **Common Side Effects**

Dizziness, headache, fatigue, nausea, low blood pressure, stomach upset, ankle swelling, flushing, tachycardia.

### **Rare but Serious Side Effects**

Severe allergic reactions, angioedema, hepatic dysfunction, renal failure, electrolyte imbalances (hypokalemia, hyponatremia).


### **Long-Term Effects**

Potential long-term effects with this combination are not specifically documented, but long-term use requires monitoring for cardiovascular and metabolic changes.

### **Adverse Drug Reactions (ADR)**

Clinically significant ADRs may include Stevens-Johnson syndrome, toxic epidermal necrolysis, severe hypotension, acute renal failure.

## **Contraindications**

- Hypersensitivity to any component of the formulation.
- Anuria (inability to produce urine).
- Severe hepatic impairment.
- Biliary obstructive disorders.
- Severe renal impairment.
- Pregnancy (especially second and third trimesters).
- Breastfeeding.
- Concomitant use of aliskiren in patients with diabetes.

## **Drug Interactions**

- Diuretics (e.g., furosemide, hydrochlorothiazide).
- Potassium supplements or potassium-sparing diuretics.
- Lithium.
- NSAIDs (e.g., ibuprofen, naproxen).
- CYP3A4 inhibitors (e.g., ketoconazole, ritonavir).
- Digoxin.
- Alcohol.
- Potassium-rich foods.


## **Pregnancy and Breastfeeding**

- **Pregnancy Safety Category:** D (There is positive evidence of human fetal risk, but potential benefits may warrant use of the drug in pregnant women despite potential risks.)
- **Breastfeeding:** This combination can potentially pass into breast milk. It's generally not recommended during breastfeeding.

## **Drug Profile Summary**

- **Mechanism of Action:** Combination of calcium channel blockade, diuresis, and angiotensin II receptor blockade.
- **Side Effects:** Dizziness, headache, fatigue, nausea, hypotension.
- **Contraindications:** Hypersensitivity, anuria, severe hepatic/renal impairment, pregnancy, breastfeeding.
- **Drug Interactions:** Diuretics, potassium supplements, lithium, NSAIDs, CYP3A4 inhibitors.
- **Pregnancy & Breastfeeding:** Contraindicated.
- **Dosage:** Adult dose is typically a combination tablet containing Benidipine 4mg, Chlorthalidone 12.5 mg, and Telmisartan 40 mg once daily, adjusted as needed.
- **Monitoring Parameters:** Blood pressure, renal function, electrolytes, liver function tests.

## **Popular Combinations**

While this itself is a triple combination, sometimes further medication might be necessary depending on individual patient condition and response.

## **Precautions**

- Monitor for allergic reactions, metabolic disorders, organ dysfunction.
- Exercise caution in pregnant and breastfeeding women.
- Adjust dosage in children and elderly patients.
- Advise patients about potential dizziness and fatigue, restricting driving and operating machinery.
- Recommend limiting alcohol consumption.


## **FAQs (Frequently Asked Questions)**

### **Q1: What is the recommended dosage for Benidipine + Chlorthalidone + Telmisartan?**

**A:** The standard adult dose is Benidipine 4mg + Chlorthalidone 12.5mg + Telmisartan 40mg once daily, but this might change depending on the patient's specific situation. This combination is generally not recommended for children.

### **Q2:  What are the main side effects?**

**A:** Common side effects include dizziness, headache, fatigue, nausea, and low blood pressure.

### **Q3: Can this combination be used during pregnancy or breastfeeding?**

**A:** No, it is contraindicated in both pregnancy and breastfeeding due to potential harm to the fetus or neonate.

### **Q4: What are the major drug interactions to be aware of?**

**A:** Significant interactions can occur with diuretics, potassium supplements, lithium, NSAIDs, and CYP3A4 inhibitors.

### **Q5: What should be monitored in patients taking this combination?**

**A:** Blood pressure, renal function, electrolytes, and liver function tests should be regularly monitored.

### **Q6: What conditions does this combination treat?**

**A:** Primarily, it is indicated for the treatment of hypertension (high blood pressure).

### **Q7:  Are there any dietary restrictions while on this medication?**

**A:** Patients should limit their intake of potassium-rich foods and avoid alcohol.

### **Q8: What should a patient do if they miss a dose?**

**A:** If a dose is missed, take it as soon as remembered unless it is close to the next scheduled dose. Do not double the dose.

### **Q9:  Is this combination safe for patients with kidney or liver problems?**

**A:** Caution is advised in patients with kidney or liver problems. Dose adjustment may be necessary depending on the severity of impairment.

### **Q10:  What is the mechanism of action of this triple-drug therapy?**

**A:** It combines the actions of a calcium channel blocker (Benidipine), a diuretic (Chlorthalidone), and an angiotensin II receptor blocker (Telmisartan) to lower blood pressure through various mechanisms.

